Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021

News
Video

Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.

CancerNetwork® sat down with Paolo Ghia, MD, from the Universita Università Vita-Salute San Raffaele, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the CAPTIVATE trial (NCT02910583) examining the chemotherapy-free regimen of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL). With the all-oral therapy regimen, patients experienced promising progression-free survival and overall survival.

Transcript:

This [regimen] is really opening a new way of treating patients with chronic lymphocytic leukemia, because so far we are used to continuing treatment, which [has] revolutionized the treatment in CLL. With the advent of oral therapies, [patients] indeed experienced increases in the progression-free survival and overall survival. Of course, having a fixed-duration treatment might be very beneficial for our patient because that would allow [us] to stop the treatment after a number of months, preventing the long-term adverse events, but also the possibility of the occurrence gene mutations and therefore resistance to the drugs.

Reference

Ghia P, Allan J, Siddiqi T et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 39;2021(suppl 15):7501. doi: 10.1200/JCO.2021.39.15_suppl.7501

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content